HALO
Halozyme Therapeutics Inc.
Company Overview
| Mkt Cap | $7.50B | Price | $65.19 |
| Volume | 1.41M | Change | +0.87% |
| P/E Ratio | 16.9 | Open | $64.10 |
| Revenue | $1.0B | Prev Close | $64.63 |
| Net Income | $444.1M | 52W Range | $42.01 - $79.50 |
| Div Yield | N/A | Target | $75.56 |
| Overall | 59 | Value | 60 |
| Quality | 76 | Technical | 41 |
No chart data available
Stock Overview
Updated DailyHalozyme Therapeutics Inc. (HALO) is a leading Healthcare company in the Biotechnology industry, currently trading at $65.19 with a market capitalization of $7.50 billion. The stock is positioned in the upper portion of its trading range, demonstrating unrated quality characteristics with a MarketXLS quality score of N/A.
Today's trading session shows HALO with a volume of 1.41 million shares. The stock opened down 0.82% from yesterday's close of $64.63. Current analyst estimates project earnings of $5.86 per share for this year, with next year targeting $7.29.
HALO demonstrates neutral technical outlook based on technical analysis. The company trades on the NGS exchange and operates alongside industry peers including MNKD, LLY, BAX, PFE, SNY.
Key investment considerations for HALO include average overall investment profile. The company offers a dividend yield of NA% and analyst price targets suggest potential upside of 15.9%. The stock shows fair valuation metrics based on valuation analysis.
Analysis generated on November 2, 2025 at 11:24 AM
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | HALO | $65.19 | +0.9% | 1.41M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Halozyme Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW